AXL Cancer Research Results

AXL, Anexelekto: Click to Expand ⟱
Source:
Type:
AXL (Anexelekto) is a receptor tyrosine kinase that plays a crucial role in the regulation of cell growth, survival, and migration.
AXL is involved in the regulation of cell growth and survival, and its overexpression has been linked to the development of cancer.
AXL works by binding to its ligand, growth arrest-specific protein 6 (GAS6), which activates the AXL receptor and triggers a signaling cascade that promotes cell growth and survival.
AXL can also interact with other proteins, including PI3K and AKT, to regulate cell growth and survival.
Scientific Papers found: Click to Expand⟱
577- Api,  PacT,    Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
- in-vitro, Ovarian, SKOV3
p‑Akt↓, Bcl-xL↓, Bcl-2↓, AXL↓, Tyro3↓,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2↓, JNK↑, Beclin-1↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2↓, MMP9↓,
2704- BBR,    Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines
- in-vitro, ESCC, KYSE450
EZH2↓, AXL↓,
5887- CAR,  TV,    Antitumor Effects of Carvacrol and Thymol: A Systematic Review
- Review, Var, NA
Apoptosis↑, TumCCA↑, TumMeta↓, TumCP↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, eff↑, *Inflam↓, *antiOx↑, AXL↓, MDA↑, Casp3↑, Bcl-2↓, MMP2↓, MMP9↓, p‑JNK↑, BAX↑, MDA↓, TRPM7↓, MMP↓, Cyt‑c↑, Casp↑, cl‑PARP↑, ROS↑, CDK4↓, P21↑, F-actin↓, GSH↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, *GSH↑, *lipid-P↓, *AST↓, *ALAT↓, *ALP↓, *LDH↓, DNAdam↑, AFP↓, VEGF↓, Weight↑, *chemoP↑, ROS↑,
6618- Ech,    Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach
- Analysis, BC, NA
AXL↓, Dose?,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   GPx↓, 1,   GSH↓, 3,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   MDA↓, 1,   MDA↑, 1,   NQO1↓, 1,   NRF2↓, 1,   ROS↑, 4,   SOD↓, 1,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↑, 1,   MMP↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PKM2↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 2,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 4,   Bcl-xL↓, 1,   Casp↑, 1,   Casp1↓, 1,   Casp3↑, 2,   Casp8↑, 1,   Cyt‑c↑, 3,   DR5↑, 2,   FADD↑, 1,   Fas↑, 2,   FasL↑, 1,   HGF/c-Met↓, 1,   JNK↑, 1,   p‑JNK↑, 2,   MAPK↓, 2,   Mcl-1↓, 1,   p‑MDM2↓, 1,   p38↑, 1,   p‑p38↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   H3↓, 1,   H4↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   PARP↑, 1,   cl‑PARP↑, 2,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycE/CCNE↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↓, 1,   cFos↑, 1,   EMT↓, 2,   HDAC↓, 1,   HH↓, 1,   mTOR↓, 2,   NOTCH1↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   PTEN↓, 1,   p‑Src↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   p‑STAT6↓, 1,   TRPM7↓, 1,  

Migration(tgid=13) ⓘ

AXL↓, 6,   Ca+2↑, 1,   CAFs/TAFs↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   F-actin↓, 1,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 2,   MMP9↓, 2,   N-cadherin↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail?, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCP↓, 2,   TumMeta↓, 2,   Twist↓, 1,   Tyro3↓, 2,   uPA↓, 1,   Vim↑, 1,   Zeb1↓, 1,   ZEB2↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↑, 1,   Hif1a↓, 1,   VEGF↓, 3,   VEGFR2↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC↓, 1,   COX2↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL2↑, 1,   IL4↓, 1,   IL6↓, 1,   M2 MC↓, 1,   NF-kB↓, 1,   p‑p65↓, 1,   PD-1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 1,   Dose?, 1,   eff↑, 7,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AFP↓, 1,   AR↓, 1,   CEA↓, 1,   EGFR↑, 1,   EZH2↓, 1,   IL6↓, 1,   Ki-67↓, 1,   NSE↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cachexia↓, 1,   chemoP↑, 1,   Weight↑, 1,  
Total Targets: 151

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   lipid-P↓, 2,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   LDH↓, 1,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,  
Total Targets: 22

Scientific Paper Hit Count for: AXL, Anexelekto
1 Apigenin (mainly Parsley)
1 Paclitaxel
1 Artemisinin
1 Berberine
1 Carvacrol
1 Thymol-Thymus vulgaris
1 Echinacea
1 Luteolin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:802  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page